SASH-B: Sodium Accumulation Study in Haemodialysis: Brain Study
Research type
Research Study
Full title
Sodium Accumulation Study in Haemodialysis: Brain Study
IRAS ID
328584
Contact name
Rebecca Noble
Contact email
Sponsor organisation
University Hospitals of Derby and Burton NHS Foundation Trust
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
NCT05966116, clinicaltrials.gov
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
Haemodialysis is a treatment which is life sustaining for patients with end stage kidney disease. Patients need treatment 3 times a week in order to clear toxins and maintain their fluid levels. One of the key elements of haemodialysis, is removal of salts such as sodium which are normally cleared by the kidneys. Sodium is important for blood pressure regulation and has a role in blood flow in the brain. Haemodialysis patients are three times more likely to develop cognitive impairment – dementia – than patients who aren’t on dialysis. Not only that but they are likely to develop problems at a younger age. We have previously found that haemodialysis itself causes changes in brain blood flow and fluid. We are now able to measure tissue sodium levels using a special MRI scan specifically measuring sodium. In this study we will do a sodium MRI brain scan on haemodialysis patients before and after a dialysis session to see what changes happen in the brain as a direct result of the treatment. If we can start to understand how brain sodium changes with dialysis, we may be able to understand the way that cognitive impairment develops and is accelerated.
REC name
London - City & East Research Ethics Committee
REC reference
23/PR/1141
Date of REC Opinion
19 Oct 2023
REC opinion
Further Information Favourable Opinion